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Abstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a 
high afﬁ  nity and speciﬁ  city for receptor activator of nuclear factor-κB ligand (RANKL), a cytokine 
member of the tumor necrosis factor family. RANKL, the principal mediator of osteoclastic bone 
resorption, plays a major role in the pathogenesis of postmenopausal osteoporosis and other skeletal 
disorders associated with bone loss. Denosumab inhibits the action of RANKL, thereby reducing 
the differentiation, activity, and survival of osteoclasts, and lowering the rate of bone resorption. 
Clinical trials have shown that denosumab increases bone mineral density (BMD) and reduces 
bone turnover in postmenopausal women with low BMD. Studies to evaluate the fracture risk 
beneﬁ  t and long-term safety of denosumab in women with postmenopausal osteoporosis (PMO) 
are ongoing. Denosumab is a potential treatment for PMO and other skeletal disorders.
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Introduction
Osteoporosis is a disease characterized by low bone mineral density (BMD) and poor 
bone quality that reduces bone strength and increases the risk of low-trauma fractures 
(Klibanski et al 2001). It is a worldwide public health problem with serious conse-
quences in terms of personal suffering and costs to society (Autier et al 2000; Burge et al 
2007). About 30% of postmenopausal Caucasian women have osteoporosis (Melton 
1995), with a lifetime fracture risk of 40% (Melton et al 1992). Fractures of the hip and 
spine are associated with increased morbidity and mortality (Cooper 1997; Center et al 
1999). Although clinical tools to diagnosis osteoporosis and predict fracture risk are 
readily available (Kanis et al 2005), patients who are at risk for fracture are often not 
recognized or treated (Solomon et al 2005). Even patients with previous fractures, who 
are at very high risk of future fracture (Johnell et al 2004), are commonly not evaluated 
or treated (Feldstein et al 2003). When patients are started on a drug for the treatment 
for osteoporosis, compliance to therapy is poor (McCombs et al 2004), with many 
studies showing less than 50% of patients still taking drug one year after it has been 
prescribed (Cramer et al 2007). Patients who are compliant to therapy have a greater 
increase in BMD (Yood et al 2003), lower fracture risk (Caro et al 2004), and reduced 
healthcare costs (McCombs et al 2004) compared to those who are not compliant.
Drugs for the treatment of osteoporosis may be classiﬁ  ed as antiresorptive (also called 
anti-catabolic) or anabolic (Riggs and Parﬁ  tt 2005), depending on their predominant effect 
on bone remodeling. Estrogens, bisphosphonates (eg, alendronate, risedronate, ibandronate, 
zoledronate), calcitonin, and raloxifene are antiresorptive agents that strengthen bone and 
reduce fracture risk. By decreasing bone turnover, these drugs stabilize or increase BMD 
by ﬁ  lling in the remodeling space and prolonging secondary mineralization, maintaining 
bone microarchitecture, reducing trabecular perforation, and decreasing cortical porosity. Biologics: Targets & Therapy 2008:2(4) 646
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Teriparatide, recombinant human parathyroid hormone (PTH) 
1–34, is an anabolic or bone-forming drug that strengthens bone 
and reduces fracture risk by increasing bone formation, which is 
associated with an increase in bone size and possibly restoration 
or formation of new trabecular microarchitectural elements. 
Strontium ranelate, which is approved in some countries for the 
treatment of osteoporosis, appears to have both antiresorptive 
and anabolic properties. While all of the approved drugs play 
a useful role in the management of osteoporosis, each has its 
limitations. Oral bisphosphonates have complex administration 
requirements (fasting, ingestion with plain water only, post-dose 
fasting) and may cause upper gastrointestinal symptoms. Intra-
venous (iv) bisphosphonates must be given by trained staff in a 
physician’s ofﬁ  ce or infusion center. Estrogen and raloxifene 
are associated with non-skeletal risks (eg, thromboembolic 
events), as well as non-skeletal beneﬁ  ts, such as reduction in 
hot ﬂ  ashes with estrogen and decreased risk of invasive breast 
cancer with raloxifene. Nasal calcitonin may be the best toler-
ated of all agents, but can cause nasal irritation in some patients. 
Teriparatide involves daily self-administered subcutaneous 
injection and is the most expensive of all approved drugs. The 
US Surgeon General has identiﬁ  ed poor adherence to therapy 
as a major obstacle in the treatment of osteoporosis, and sug-
gested that less frequent dosing and simpliﬁ  ed drug administra-
tion be considered as a potential means to improve adherence 
(US Department of Health and Human Services 2004).
Denosumab (AMG 162; Amgen Inc., Thousand Oaks, 
CA, USA) is an investigational drug with a novel mechanism 
of action that is being developed for use in the management 
of postmenopausal osteoporosis (PMO). Administered as a 
subcutaneous injection (SC) at intervals as long as 6 months, 
it addresses some of the concerns raised by the US Surgeon 
General regarding poor adherence to therapy and may over-
come some of the limitations of currently available drugs. 
Denosumab is now in phase 3 clinical trials for the preven-
tion and treatment of postmenopausal osteoporosis and other 
skeletal diseases associated with bone loss.
Denosumab structure 
and mechanism of action
Denosumab is a fully human monoclonal antibody (IgG2 
immunoglobulin isotype) with a high afﬁ  nity and speciﬁ  c-
ity for human receptor activator of nuclear factor-κB ligand 
(RANKL). It is manufactured with XenoMouse® (Abgenix, 
Inc., Fremont, CA, USA) technology using a mouse strain 
engineered to produce a wide range of human antibodies 
in the absence of mouse antibodies. Denosumab is a potent 
inhibitor of osteoclastic bone resorption. By binding to 
RANKL in a manner similar to native osteoprotegerin 
(OPG), denosumab prevents the interaction of RANKL and 
RANK. This reduces the differentiation, activity, and sur-
vival of osteoclasts, thereby inhibiting bone resorption.
Physiology of the adult skeleton
The adult human skeleton is a metabolically active organ 
system that is continually renewed through the process of 
bone remodeling (bone turnover). Packets of bone collagen 
and mineral are resorbed (removed) and formed (replaced) in 
small discreet cavities. These cavities form pits or trenches 
on the surfaces of trabecular (cancellous) bone and tunnels 
or canals within cortical bone in Haversian systems. Bone 
remodeling is essential for mineral homeostasis and mainte-
nance of bone viability, including the replacement of apop-
totic osteocytes and repair of microdamage. In healthy adults 
with stable bone mass, the rate of bone turnover is moderate 
with resorption and formation being of approximately equal 
magnitude. Excessive remodeling (high bone turnover) 
diminishes bone strength independently of BMD, primarily 
because excessive numbers of cavities act as “stress risers” – 
weakened areas of bone that may be a source of microcracks. 
High bone turnover also weakens bone due to loss of BMD 
associated with microarchitectural deterioration of bone 
tissue (eg, trabecular thinning, trabecular perforation, loss 
of trabecular connectivity, cortical thinning, and increased 
cortical porosity) and diminished mineralization. When bone 
resorption is greater than bone formation, as typically occurs 
in early postmenopausal estrogen-deﬁ  cient women, there is 
a net loss of bone over time. If unchecked, this can eventu-
ally result in low bone mass (osteopenia) or osteoporosis. In 
physiological states and with most metabolic bone diseases 
there is “coupling” of bone resorption and bone formation, 
ie, a sequence of events where osteoclastic bone resorption 
is predictably followed by osteoblastic bone formation. As 
bone resorption rises or falls, so does bone formation. When 
formation fails to keep up with resorption, bone loss occurs, 
and when formation exceeds resorption, there is a net increase 
in bone mass. The cellular and humoral factors that regulate 
bone remodeling are the focus of great interest, with advances 
in this ﬁ  eld providing a better understanding of the origins of 
skeletal health and disease, and suggesting possible targets for 
pharmacological interventions to treat skeletal diseases.
Regulation of bone remodeling
While there are numerous systemic and local factors 
involved in the regulation of bone remodeling, the principal 
ﬁ  nal mediator of osteoclastic bone resorption is RANKL, Biologics: Targets & Therapy 2008:2(4) 647
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a cytokine member of the tumor necrosis factor (TNF) 
superfamily (Boyle et al 2003). RANKL is a 316 amino acid 
transmembrane protein that is highly expressed by osteoblasts 
and T cells (Collin-Osdoby 2004). It is also found in two 
biologically active soluble forms derived by cleavage from 
the osteoblast cell surface or secreted from T cells. Receptor 
activator of nuclear factor-κB (RANK), located on the cell 
membrane of osteoclasts and pre-osteoclasts (Hsu et al 1999), 
is a 616 amino acid transmembrane receptor for RANKL. 
RANKL-RANK binding stimulates the differentiation, 
activity, and survival of osteoclasts, resulting in increased 
bone resorption (Lacey et al 1998). Soluble RANKL injected 
into mice results in a measurable increase in bone resorption 
within 60 minutes (Burgess et al 1999). Osteoprotegerin 
(OPG), a 380 amino acid member of the TNF receptor 
superfamily, is a soluble non-signaling “decoy receptor” for 
RANKL. By binding to RANKL and preventing its interac-
tion with RANK, OPG inhibits osteoclast differentiation 
(Simonet et al 1997; Lacey et al 1998), activity (Mosekilde 
et al 1991; Burgess et al 1999), attachment to the bone surface 
(O’Brien et al 2000, 2001) and survival (Lacey et al 2000), 
thereby reducing bone resorption (Simonet et al 1997). An 
increase in RANKL in proportion to OPG is associated with 
the development of postmenopausal osteoporosis and other 
skeletal disorders that include multiple myeloma, metastatic 
bone disease, treatment-related bone loss, rheumatoid arthri-
tis, and Paget’s disease of bone (Lacey et al 1998; Boyle et al 
2003; Hofbauer and Schoppet 2004). RANKL expression 
on osteoblasts is upregulated by such diverse signals as 
PTH, 1,25-dihydroxyvitamin D (1,25-[OH]2-D), calcium, 
glucocorticoids, prostaglandin E2, inteleukin (IL)-1α, 
IL-6, IL-11, and IL-17, and downregulated by transform-
ing growth factor (TGF)-β. OPG is increased by signals 
that include 1,25-(OH)2-D, calcium, IL-1α, IL-6, IL-11, 
IL-17, estrogen, TGF-β, and bone morphogenetic protein 
(BMP)-2, and decreased by continuous administration of 
PTH, glucocorticoids, prostaglandin E2, and insulin-like 
growth factor 1 (Collin-Osdoby 2004). In patients with pri-
mary hyperparathyroidism, an elevated RANKL:OPG ratio 
was observed using assays for RANKL and OPG mRNA 
on transiliac bone biopsy, with a signiﬁ  cant decrease after 
parathyroidectomy (Stilgren et al 2004). Intermittent PTH 
therapy in women with glucocorticoid-induced osteoporosis 
modulates serum levels of RANKL and OPG (Buxton et al 
2004), suggesting that the RANKL/RANK/OPG signaling 
pathway participates in the therapeutic effects of this agent. 
Flow cytometry of bone marrow cells of pre- and post-
menopausal women showed upregulation of RANKL after 
menopause (Eghbali-Fatourechi et al 2003), consistent with 
RANKL playing a role in high bone turnover and bone loss 
commonly associated with this population.
RANKL inhibition and immune 
function
RANKL is expressed not only by osteoblasts and pre-
osteoblasts, by also by endothelial cells, stromal cells, primi-
tive mesenchymal cells surrounding cartilage, chondrocytes, 
activated T lymphocytes, and immature CD4/CD8 thymo-
cytes. RANK is expressed on the surface of chondrocytes, 
mammary gland epithelial cells, trophoblast cells, dendritic 
cells, and mature T cells, as well as on the surface of osteo-
clasts. OPG is produced and released by cells that include 
osteoblasts, dendritic cells, and lymphocytes, and OPG is 
expressed in organs that include the heart, lung, spleen, 
thymus, kidney and intestine (Neumann et al 2005). Evidence 
is accumulating that bone remodeling is modulated through 
a complex interaction of osteoclasts and osteoblasts with 
immune cells (eg, T and B lymphocytes, dendritic cells), 
cytokines (eg, interleukin-1, interleukin-6, tumor necrosis 
factor-α), and circulating hormones (eg, vitamin D, para-
thyroid hormone, testosterone, leptin) (Clowes et al 2005). 
A local or systemic imbalance in these factors may result in 
bone loss, as commonly occurs in many chronic inﬂ  amma-
tory diseases. It has been demonstrated that activated T cells 
directly stimulate osteoclastogenesis through RANKL (Kong 
et al 1999a). It is a fundamental concept of osteoimmunology 
that RANKL produced by activated T and B lymphocytes 
increases bone resorption through its interaction with osteo-
clast precursors and that RANKL also prolongs the survival 
of dendritic cells, thereby increasing T cell activity (Wong 
et al 1997; Josien et al 1999; Xing et al 2005).
The intimate relationship of bone remodeling with 
RANKL/RANK/OPG signaling and regulators of immune 
function has raised concern that agents that inhibit RANKL 
could have adverse effects on the immune response to 
infection or malignancy (Whyte 2006). Preclinical studies 
suggest that the development of an intact immune system is 
dependent on the RANKL/RANK/OPG pathway. RANK 
knockout mice, for example, have a deﬁ  ciency of splenic 
B cells and impaired lymph node organogenesis (Dougall 
et al 1999; Kong et al 1999b). In contrast, the RANKL/
RANK/OPG system appears to have a non-essential role 
in immune function for adults who already have a fully 
developed immune system. Studies in OPG transgenic rats 
and mice that overexpress OPG to levels 100-fold greater 
than wild type animals have enhanced understanding of Biologics: Targets & Therapy 2008:2(4) 648
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the prenatal role of RANKL/RANK/OPG signaling on the 
skeleton and the immune system. These animals have normal 
lymph node formation and normal immune systems (Stolina 
et al 2007), suggesting that profound inhibition of RANKL 
prenatally is not harmful to the development of an intact 
immune system in rodents, and that only small quantities of 
RANKL are sufﬁ  cient for lymph node formation.
Pharmacokinetics and metabolism 
of denosumab
The pharmacokinetics of denosumab are nonlinear with dose, 
as has been observed with other fully human monoclonal anti-
bodies. Although the absorption, bioavailability, distribution, 
and elimination of denosumab have not been well deﬁ  ned, 
studies of other therapeutic monoclonal IgG antibodies given 
by the sc route provide insight into what is likely with deno-
sumab. Studies with similar IgG antibodies suggest that SC 
denosumab is probably absorbed via the lymphatic system, 
with subsequent drainage of lymph ﬂ  uid into the vascular 
system (Lobo et al 2004). Bioavailability is probably in the 
range of 50%–100%, with a distribution that is about the 
same as the plasma volume (Lobo et al 2004; Tang et al 
2004). Clearance is probably by the reticuloendothelial sys-
tem (Lobo et al 2004). No signiﬁ  cant amount of circulating 
denosumab appears to be ﬁ  ltered and excreted by the kidneys. 
In a phase 1 dose-escalation trial of denosumab given as a 
single sc dose to healthy postmenopausal women, 3 phases 
were reported: a prolonged absorption phase with maximum 
serum concentration (Cmax) at 5–21 days post-dose, increas-
ing as the dose increased; a prolonged β-phase, with serum 
half-life as long as 32 days with the maximum dose; and a 
rapid terminal phase when serum concentration fell below 
1000 ng/mL (Bekker et al 2004). When denosumab is given 
as a 60 mg sc dose every 6 months, currently being studied 
in phase 3 clinical trials for the prevention and treatment of 
PMO, the median time to maximum concentration (Tmax) after 
the ﬁ  rst dose is 26 days (Peterson et al 2005). Denosumab 
is a more potent antiresorptive agent with a longer duration 
of antiresorptive effect than equivalent doses of OPG-Fc 
(a fusion molecule of recombinant OPG with the Fc fragment 
of IgG), evaluated in early clinical trials of RANKL inhibi-
tion (Bekker et al 2001; Body et al 2003). The long duration 
of denosumab activity can be attributed to its long half-life 
as well as effects in inhibiting osteoclast recruitment and 
activity. Preclinical models have suggested that the delay in 
osteoclast recovery observed after withdrawal of RANKL 
inhibition is due to the time necessary for osteoclasts to 
regenerate from precursor cells (Lacey et al 2000; Capparelli 
et al 2003). A feature distinguishing denosumab from the 
bisphosphonates is the rapid reversibility of its antiresorptive 
effect once it has been eliminated and osteoclast regeneration 
has occurred, since it is not incorporated into bone matrix, 
as are the bisphosphonates.
Preclinical studies of RANKL 
inhibition
RANKL is the principal ﬁ  nal mediator of osteoclastic bone 
resorption. This has been well documented in preclinical 
studies evaluating the role of the RANKL/RANK/OPG 
signaling pathway in the regulation of bone remodeling. In 
cell cultures, RANKL induces osteoclast-like cell formation 
(Matsuzaki et al 1998). Recombinant OPG inhibits osteoclast 
differentiation in a dose-dependent manner (Simonet et al 
1997). Osteotropic hormones and cytokines are have been 
observed to regulate expression of RANKL and OPG in 
human-derived osteoblast cell lines (Hofbauer et al 1999). 
OPG knockout mice develop osteoporosis and fragility 
fractures (Bucay et al 1998). RANKL knockout mice (Kong 
et al 1999b) and RANK knockout mice (Li et al 2000) have 
osteopetrosis associated with a total absence of osteoclasts.
Because of the high speciﬁ  city of denosumab for human 
RANKL, most preclinical studies of RANKL inhibition in 
mice and rats must use agents other than denosumab. The 
compounds most commonly used are fusion molecules of 
recombinant OPG or RANK and the Fc fragment of IgG, 
called OPG-Fc or RANK-Fc, respectively. Recombinant 
OPG prevents bone loss in ovariectomized (OVX) rats 
(Simonet et al 1997). Recombinant OPG decreases osteoclast 
differentiation in normal mice, resulting in non-lethal osteo-
petrosis (Simonet et al 1997). In mice with low BMD that 
overexpress TNF-α, recombinant OPG prevents bone loss 
(Schett et al 2003). RANKL inhibition increases bone min-
eralization and improves mechanical strength in the femur 
of young male rats (Ross et al 2001). In a study of aged 
OVX rats, a combination of recombinant rat OPG and PTH 
increased BMD more than either agent alone (Kostenuik et al 
2001). Intact 4- to 5-year-old male cynomolgus monkeys 
treated with denosumab were observed to have an increase 
in bone mass and improvement in bone strength with three-
point bending of the femur and compression testing of lumbar 
vertebral bodies (Atkinson et al 2005). Preclinical models 
of rheumatoid arthritis (Redlich et al 2002), ovariectomy 
(Kostenuik et al 2004), multiple myeloma (Vanderkerken 
et al 2003), and inﬂ  ammatory bowel disease (Byrne et al 
2005) have demonstrated skeletal beneﬁ  t with RANKL 
inhibition.Biologics: Targets & Therapy 2008:2(4) 649
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Knockin technology has recently been used to replace 
the 5th exon of the murine RANKL gene with a hybrid exon 
containing the coding region for the 5th exon of the human 
RANKL gene (plus a murine non-coding region), resulting 
in genetically engineered mice expressing a chimeric form 
of RANKL (human/murine) that is bound and neutralized 
by denosumab (Kostenuik et al 2005). This non-primate 
model has subsequently provided a platform for evaluating 
the skeletal effects of denosumab in variety of circumstances 
with potential human applications (Ferrari et al 2007; 
Hofbauer et al 2007).
Clinical studies of RANKL 
inhibition: efﬁ  cacy
OPG-Fc in healthy postmenopausal 
women
The ﬁ  rst study of RANKL inhibition in humans was con-
ducted with OPG-Fc. This was a phase 1 randomized, 
double-blind, placebo-controlled, sequential dose escalation 
study in healthy postmenopausal women (Bekker et al 2001). 
Each of the 52 subjects in this study received a single SC 
dose of OPG-Fc 0.1, 0.3, 1.0, 3.0 mg/kg, or placebo. All 
subjects received physical exams and laboratory studies 
that included hematology, blood chemistries, coagulation 
studies, immunoglobulins, T cell enumeration (CD3, CD4, 
CD8), bone turnover markers, and neutralizing antibodies to 
OPG. The highest dose (3.0 mg/kg) resulted in a decrease of 
urinary N-telopeptide (NTX), a marker of bone resorption, 
within 12 hours of dosing. Maximum suppression of NTX 
was approximately 80% below baseline after 3 days, with 
a subsequent slow rise to 14% below baseline at 6 weeks. 
There was a decline in bone-speciﬁ  c alkaline phosphatase 
(BSAP), a marker of bone formation, that began about 
3 weeks after dosing, reaching a low point of about 30% 
below baseline at 6 weeks. This pattern of rapid and pro-
found suppression of bone resorption with slower and less 
pronounced suppression of bone formation is similar to what 
was observed in preclinical studies. This study showed that 
a single dose of OPG-Fc caused a rapid, reversible, and 
dose-dependent suppression of bone resorption. OPG-Fc 
was not associated with serious adverse events, dropouts 
due to adverse events, or neutralizing antibodies to OPG. 
The most common adverse event was a mild injection site 
reaction. The ﬁ  ndings of this study provided support for 
further clinical development of RANKL inhibition with 
denosumab, an agent having greater antiresorptive potency 
and longer duration of action than OPG-Fc.
Denosumab in healthy postmenopausal 
women
A phase 1 single-dose, randomized, double-blind, placebo-
controlled, dose escalation study of denosumab was 
conducted in healthy postmenopausal women (Bekker et al 
2004). There were 49 subjects in this study, each of whom 
was given a single SC dose of denosumab 0.01, 0.03, 0.1, 
0.3, 1.0, or 3.0 mg/kg, or placebo. They were followed 
for as long as 6 months in all cohorts and 9 months in the 
cohorts receiving the 3 highest doses. Drug safety, toler-
ability, pharmacokinetics, and effects on bone turnover 
markers were evaluated. Suppression of urinary NTX was 
dose-dependent, rapid (as early as 12 hours, the ﬁ  rst time of 
measurement), profound (as much as 84% reduction from 
baseline), sustained (as long as 6 months), and reversible 
(increasing at the end of the monitoring period). Suppres-
sion of BSAP occurred later and was less pronounced than 
NTX. Subsequent clinical investigation of denosumab was 
undertaken in the study described below.
Denosumab in postmenopausal women 
with low BMD
A phase 2 randomized, placebo-controlled, dose-ranging 
study was conducted to evaluate the efﬁ  cacy and safety of 
denosumab in postmenopausal women with low BMD, having 
a lumbar spine T-score of –1.8 to –4.0, or total hip or femoral 
neck T-score of –1.8 to –3.5 (McClung et al 2006; Lewiecki 
et al 2007; Miller et al 2008). Study subjects were randomized 
to 9 groups of 41–54 women, with each group assigned to 
receive SC denosumab 6, 14, or 30 mg every 3 months or 14, 
60, 100, or 210 mg every 6 months; open-label alendronate 70 
mg weekly; or placebo. All study subjects received daily oral 
supplements of calcium (1000 mg) and vitamin D (400 IU). 
The mean age of randomized subjects was 63 years, with all 
groups well matched for demographics and baseline charac-
teristics. The ethnicity classiﬁ  cation was 85% white, 11% 
hispanic, and 3% black. The primary endpoint was the per-
centage change in lumbar spine (L1–L4) BMD at 12 months 
compared to baseline. Percentage change from baseline in 
BMD at the total hip, femoral neck, distal one-third radius, 
total body minus head were also assessed. Bone turnover was 
evaluated by measurement of serum CTX, urinary NTX, and 
BSAP. A total of  412 women were enrolled in the study, with 
369 (90%) completing 12 months of treatment.
At 12 months, treatment with denosumab was associated 
with a lumbar spine BMD increase of 3.0% to 6.7%, 
depending on dose and dosing interval, while there was a Biologics: Targets & Therapy 2008:2(4) 650
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0.8% loss with placebo (p   0.001 for difference) (McClung 
et al 2006). At the total hip, there was a BMD increase of 
1.9% to 3.6% from baseline, while a 0.6% loss was observed 
in the placebo group (p   0.001 for difference). At the distal 
one-third radius, there was a BMD increase of 0.4%–1.3% 
from baseline with denosumab, compared to a 2.0% loss 
with placebo (p   0.001 for difference). In an exploratory 
comparison with open-label alendronate, denosumab 30 mg 
every 3 months and 60 mg every 6 months were associated 
with a similar BMD responses at the lumbar spine and 
apparently greater BMD increases at the total hip and distal 
one-third radius. Denosumab-treated patients had a decrease 
in serum CTX compared to placebo (p   0.001) that was 
observed as early as 3 days, the ﬁ  rst scheduled time of CTX 
measurement. Serum CTX suppression reached a maximum 
mean decrease of 87.8% compared to 4.2% with placebo. 
The effects on urinary NTX were similar to serum CTX. 
Denosumab was associated with suppression of BSAP 
compared to placebo (p   0.001) that was delayed by about 
1 month compared to CTX. The suppression of bone turn-
over was dose-dependent, rapid, sustained, and reversible. 
The data suggested that denosumab 60 mg every 6 months 
and 30 mg every 3 months were associated with maximum 
therapeutic beneﬁ  t and minimal exposure dose.
A prespeciﬁ  ed exploratory analysis evaluated the efﬁ  cacy 
and safety of denosumab after 24 months or treatment 
(Lewiecki et al 2007). Outcome measures included BMD at 
the lumbar spine, total hip, distal one-third radius, and total 
body, as well as bone turnover markers and safety. Of the 
original 412 women randomized, 337 (81.8%) completed 
the 24 month study. BMD increases at the lumbar spine at 
24 months ranged from 4.13% to 8.89% with denosumab 
compared to a 1.18% decrease with placebo (p   0.001 for 
all doses denosumab vs. placebo). The percentage changes in 
lumbar spine BMD from baseline for all doses of denosumab 
doses were greater than for placebo from month 3 to month 
24 (p   0.001). At 24 months, all doses of denosumab were 
associated with BMD increases at the total hip, one-third 
radius, and total body compared to placebo (p   0.001). 
Compared to open label alendronate, BMD increases with 
denosumab at all four skeletal sites were similar or greater, 
except with the denosumab dose of 14 mg every 6 months, 
for which the BMD change at the lumbar spine was less 
than with alendronate. With the denosumab dose of 60 mg 
every 6 months (the dose being studied in a phase 3 frac-
ture prevention trial), the BMD changes from 12 months to 
24 months were evaluated. The BMD increase during the 
second 12 months of the study was 2.75% at the lumbar 
spine (p   0.001) and 1.50% at the total hip (p   0.001), with 
numerically greater but statistically insigniﬁ  cant changes in 
BMD at the distal one-third radius and total body.
Ongoing clinical trials with denosumab
Phase 3 trials are currently underway to evaluate the safety and 
efﬁ  cacy of denosumab in reducing vertebral fracture risk in 
women with PMO, prevention of bone loss in postmenopausal 
women with low BMD (osteopenia), prevention of bone loss 
in women with non-metastatic breast cancer on aromatase 
inhibitor therapy, and prevention of bone loss in men with non-
metastatic prostate cancer on androgen deprivation therapy. 
Ongoing phase 2 trials include the evaluation of denosumab 
in patients with rheumatoid arthritis, bisphosphonate-naïve 
patients with breast cancer, and patients receiving intravenous 
bisphosphonates for advanced cancer metastatic to bone.
An interim analysis of treatment with 5 dosing regimens of 
denosumab in 255 bisphosphonate naïve patients with breast 
cancer-related bone metastases has been reported (Lipton 
et al 2007). In this phase 2, randomized, active-controlled, 
multi-center, multidose, parallel group study, patients were 
randomized to receive SC denosumab 30, 120, or 180 mg 
every 4 weeks, 60 or 180 mg every 12 weeks, or open-
label iv bisphosphonate (zoledronic acid, pamidronate, or 
ibandronate at the physician’s discretions) every 4 weeks. 
After 13 weeks of treatment, the median percentage reduction 
in urinary NTX/creatinine ratio (uNTX/Cr) was 71% for the 
pooled denosumab groups and 79% for the IV bisphosphonate 
group. Overall, 74% of denosumab-treated patients achieved 
more than a 65% reduction in uNTX/Cr compared to 63% 
for the bisphosphonate-treated patients. The greatest overall 
median suppression of uNTX/Cr at 13 weeks was observed 
with denosumab 120 mg every 4 weeks.
Safety and tolerability 
of denosumab
In the phase 1 study of denosumab in healthy postmeno-
pausal women, there were no drug-related serious adverse 
events and no discontinuations from the study due to adverse 
events (Bekker et al 2004). Mild transient dose-dependent 
decreases in albumin-adjusted serum calcium and corre-
sponding increases in serum intact parathyroid (iPTH) levels 
were observed. Infectious adverse events were similar with 
denosumab (38% in the combination of all treatment groups) 
and placebo (33%). Two subjects treated with denosumab 
(1.0 and 3.0 mg/kg) had mild injection site reactions. No 
denosumab-associated changes in white blood cell (WBC) 
counts, T, B, or NK cell counts (CD3, CD4, CD8, CD20, Biologics: Targets & Therapy 2008:2(4) 651
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CD56), immunoglobulins, or coagulation parameters were 
reported.
The 12-month report of the phase 2 study of denosumab 
in women with low BMD described a small, transient, 
asymptomatic, non-dose dependent decrease in the mean 
albumin-adjusted serum calcium in patients treated with 
denosumab compared to placebo and alendronate (McClung 
et al 2006). The mean serum iPTH increased with denosumab 
and alendronate compared to placebo, with a return toward 
baseline values over time. There were no signiﬁ  cant differ-
ences in the percentage of subjects having adverse events with 
denosumab, placebo, and alendronate, with the exception of 
dyspepsia being most common with open-label alendronate. 
Two subjects receiving denosumab 100 mg every 6 months 
developed transient non-neutralizing denosumab-binding 
antibodies. In a subset of denosumab-treated subjects who 
had immune function evaluated, there were no clinically 
meaningful changes in white blood cell counts, T cell, 
B cell or NK cell (CD3, CD4, CD8, CD19, and CD16/56) 
enumeration by ﬂ  ow cytometry at 1-year (Cohen et al 2005). 
There was no evidence that denosumab was associated with 
an increased risk of infection, malignancy, over-suppression 
of bone turnover, or impaired fracture healing. There were no 
reported cases of osteonecrosis of the jaw with denosumab.
Over the ﬁ  rst 24 months of the phase 2 trial, adverse 
events continued to be generally similar in the placebo, deno-
sumab, and alendronate groups (Lewiecki et al 2007). There 
were 6 cases (1.9%) of serious adverse events of infections 
in the denosumab group (2 cases of diverticulitis, 3 cases of 
pneumonia, and 1 case of labyrinthitis) compared to none 
in the placebo group or open label alendronate group. There 
was 1 death, caused by gastric cancer, in the denosumab 
group, and none in the placebo or alendronate groups. Dis-
continuation rates over the ﬁ  rst 24 months were 2.2% for 
placebo, 2.9% for denosumab, and 6.4% for alendronate. 
No neutralizing antibodies to denosumab were observed in 
the ﬁ  rst 24 months of treatment.
In the 13 week interim analysis of safety data in the phase 
2 trial of denosumab in women with breast cancer-related 
bone metastases, 8% of denosumab-treated patients experi-
enced transient asymptomatic decreases in serum calcium 
compared to 5% of IV bisphosphonate-treated patients 
(Lipton et al 2007). Serious adverse events in the study were 
similar for those treated with denosumab and bisphospho-
nates, with none of the serious adverse events attributed to 
denosumab or iv bisphosphonate. There was no apparent 
increase in the rate of infections or cardiovascular events in 
denosumab-treated patients, and no reports of osteonecrosis 
of the jaw. Injection-site reactions were reported in 3% of 
denosumab-treated patients and no IV bisphosphonate-
treated patients.
There is no evidence that RANKL inhibition in humans 
has adverse effects on immune function (Bekker et al 2001, 
2004; McClung et al 2006).
Potential role of denosumab 
in the management of PMO
As denosumab in currently available for investigational use 
only, and studies phase 3 trials evaluating prevention of 
bone loss in postmenopausal women with low bone mass 
and reduction of fracture risk in women with PMO have 
not been completed, it is purely speculative to consider its 
potential role in clinical practice. However, the published 
data to date suggest that it may have some advantages over 
therapeutic agents that are now approved. The SQ method of 
dosing is likely to expand the number of physicians willing to 
administer the drug compared to iv bisphosphonates, which 
are primarily given at infusion centers and by physicians 
specializing in osteoporosis. The long dosing interval of 
6 months assures adherence to therapy for that length of 
time- a potential advantage over oral agents administered 
daily, weekly, or monthly.
If the phase 3 trials demonstrate efﬁ  cacy that is similar 
to the bisphosphonates, with a good safety proﬁ  le, then the 
target population may largely depend on cost- an unknown 
value at this time. If the cost is sufﬁ  ciently low, denosumab 
might be considered as “ﬁ  rst-line” therapy for PMO. If 
the cost is similar to branded oral or IV bisphosphonates, 
as is more likely to be the case, then drug selection for an 
individual patient may depend on availability, previous 
experience (if any) with bisphosphonates, and convenience 
of administration.
Although it is unlikely that a large head-to-head clinical 
trial comparing denosumab and bisphosphonates, with frac-
tures as the primary endpoint, will ever be conducted, studies 
comparing surrogates of bone strength may show some differ-
ences between these drug classes. If denosumab has a greater 
effect on cortical bone than bisphosphonates, as suggested 
by differences in BMD response at the radius compared to 
alendronate in a phase 2 clinical trial (Lewiecki et al 2007), 
then it could have some theoretical advantages in the treatment 
of patients at high risk for non-vertebral fractures.
Finally, preclinical studies showing an additive effect 
of OPG and PTH on BMD suggest a potential role for 
combination therapy with denosumab and anabolic agents. 
Further study is needed to test this hypothesis.Biologics: Targets & Therapy 2008:2(4) 652
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Summary
Denosumab is an investigational fully human monoclonal 
antibody with high afﬁ  nity and speciﬁ  city to RANKL, the 
principal mediator of osteoclastic bone resorption. It sup-
presses bone resorption in a rapid, sustained, and reversible 
manner. Denosumab treatment, given as a sc injection with 
a dosing frequency as long as 6 months, increases BMD and 
reduces bone turnover in postmenopausal women with low 
BMD. Reported adverse events in a phase 2 clinical trial in 
women with low BMD were similar to placebo and open-
label alendronate. Denosumab is a promising therapeutic 
agent for the management of postmenopausal osteoporosis 
and other skeletal diseases associated with bone loss. Phase 
3 trials to evaluate the efﬁ  cacy of denosumab to reduce the 
risk of fractures in women with PMO or prevent bone loss in 
individuals with other skeletal disorders are ongoing.
Note
Amgen released a press release on July 25, 2008 (http://www.
amgen.com/media/media_pr_detail.jsp?releaseID=1179628) 
announcing the results of a pivotal, three-year, international, 
phase 3 study of denosumab in women with osteoporosis.
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